PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer

Radiation Oncology Investigations

Volumn 7, Issue 1, 1999, Pages 30-35

  Iannuzzi, Christopher M ^a   Stock, Richard G ^a,b   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

1 125; Brachytherapy; Prostate cancer; PSA kinetics

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIOISOTOPE THERAPY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE;

ADENOMA; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0033028826     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:1<30::AID-ROI4>3.0.CO;2-8     Document Type: Article

References (20)

1. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated with radiation therapy. J Urol 1994;152:1786-1791.
2. Zeitman AI, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-645.
3. Kaplan I, Cox R, Bagshaw M. Prostate specific antigen after external beam radio-therapy for prostate cancer: follow up. J Urol 1993;149:519-522.
4. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determination before and after radical prostatectomy. J Urol 1989;141:873-879.
5. American Health Consultants. BBI Newsletter 1996;14.
6. Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995;32:219-225.
7. Stone NN, Stock RG, DeWyngaert JK, Tabert A. Prostate brachytherapy: improvement in prostate volume measurements and dose distribution using interactive ultrasound-guided implantation and three-dimensional dosimetry. Radiat Oncol Invest 1995;3:185-195.
8. Stock RG, Stone NN. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 1997;13:454-460.
9. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-481.
10. Cox DR, Oakes D. Analysis of survival data. Chapman and Hall; 1984.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
12. Feinberg SE. The analysis of cross-classified categorical data, 2nd ed. Cambridge, Mass.: MIT Press; 1980.
13. Stamey TA, Yang N, Hay AR, McNeil JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909.
14. Lightner DJ, Lange PH, Reddy PK, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:922-926.
15. Willett CG, Zeitman AL, Shipley WU, Coen JJ. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 1994;151:1579-1581.
16. Kavadi VS, Zagars GK, Pollack A. Serum prostate specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994;30:279-287.
17. Ragde H, Blasko JC, Grimm PD. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997; 80:442-450.
18. Ben-Josef E, Shamsa F, Smith D, et al. Early prediction of outcome radiotherapy for localized prostate cancer using the pattern of PSA decline. Radiother Oncol [Suppl] 1994;32.
19. Ginor RX, Zelefsky M. Efficacy of alpha 1 blocker therapy in the treatment of acute grade II urinary symptoms during radiotherapy for localized prostate cancer. J Urol [Suppl] 1997;157:287.
20. Zagars GK, Pollack A. The serum prostate specific antigen level three months after radio-therapy for prostate cancer: an early indicator of response to treatment. Radiat Oncol 1994;30:121-127.